1887

Abstract

The antibacterial mechanisms of rhodomyrtone, a member of the acylphloroglucinols isolated from leaves, against important hospital-acquired antibiotic-resistant pathogenic bacteria were assessed. The results indicated that rhodomyrtone exhibited pronounced antibacterial activity against key antibiotic-resistant pathogens including epidemic meticillin-resistant (EMRSA), vancomycin-intermediate and vancomycin-resistant enterococcal strains. The strains EMRSA-16, ATCC 29212 and VRE-3 demonstrated a significant decrease in survival ability after treatment with rhodomyrtone at 1× (0.5 µg ml), 2×, 4× and 8× MIC for 24 h. Moreover, the compound was observed in the cytoplasmic fraction of rhodomyrtone-treated , and only a very fine band of the compound was seen following separation of the cell-wall and cell-membrane fractions of the treated cells. In addition, exposure of to rhodomyrtone at 4×, 2× and 1× MIC for 24 h produced no significant effect on the bacterial cell membrane and cell lysis, suggesting that neither of these is the main target of rhodomyrtone action in these organisms. Stepwise isolation of the bacterial cells with increasing resistance to rhodomyrtone was not induced in either or EMRSA-16 after 45 passages on Luria–Bertani agar supplemented with rhodomyrtone. In addition, toxicity of rhodomyrtone at 128× MIC on human erythrocytes was not observed. These results provide evidence to support therapeutic challenges of rhodomyrtone against Gram-positive pathogens.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.049205-0
2013-01-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/1/78.html?itemId=/content/journal/jmm/10.1099/jmm.0.049205-0&mimeType=html&fmt=ahah

References

  1. Alder J. D. 2005; Daptomycin: a new drug class for the treatment of Gram-positive infections. Drugs Today (Barc) 41:81–90 [View Article][PubMed]
    [Google Scholar]
  2. Aligholi M., Emaneini M., Jabalameli F., Shahsavan S., Dabiri H., Sedaght H. 2008; Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med Princ Pract 17:432–434 [View Article][PubMed]
    [Google Scholar]
  3. Bibi Y., Nisa S., Chaudhary F. M., Zia M. 2011; Antibacterial activity of some selected medicinal plants of Pakistan. BMC Complement Altern Med 11:52 [View Article][PubMed]
    [Google Scholar]
  4. Bilal M., Cleveland K. O., Gelfand M. S. 2009; Community-acquired methicillin-resistant Staphylococcus aureus and Lemierre syndrome. Am J Med Sci 338:326–327 [View Article][PubMed]
    [Google Scholar]
  5. Bogomolova N. S., Bol’shakov L. V., Kuznetsova S. M., Oreshkina T. D. 2011; [Antibiotic resistance dynamics and isolation rate of staphylococci and enterococci from patients of reconstructive surgery units]. Antibiot Khimioter 56:37–45 (in Russian) [PubMed]
    [Google Scholar]
  6. Brusselaers N., Vogelaers D., Blot S. 2011; The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 1:47 [View Article][PubMed]
    [Google Scholar]
  7. Carson C. F., Mee B. J., Riley T. V. 2002; Mechanism of action of Melaleuca alternifolia (tea tree) oil on Staphylococcus aureus determined by time-kill, lysis, leakage, and salt tolerance assays and electron microscopy. Antimicrob Agents Chemother 46:1914–1920 [View Article][PubMed]
    [Google Scholar]
  8. Chusri S., Voravuthikunchai S. P. 2011; Damage of staphylococcal cytoplasmic membrane by Quercus infectoria G. Olivier and its components. Lett Appl Microbiol 52:565–572 [View Article][PubMed]
    [Google Scholar]
  9. CLSI 2009 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, approved standard, 8th edn. Wayne, PA: Clinical and Laboratory Standards Institute
  10. Cui L., Ma X., Sato K., Okuma K., Tenover F. C., Mamizuka E. M., Gemmell C. G., Kim M. N., Ploy M. C. other authors 2003; Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus . J Clin Microbiol 41:5–14 [View Article][PubMed]
    [Google Scholar]
  11. Cui L., Iwamoto A., Lian J. Q., Neoh H. M., Maruyama T., Horikawa Y., Hiramatsu K. 2006; Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus . Antimicrob Agents Chemother 50:428–438 [View Article][PubMed]
    [Google Scholar]
  12. Cunha B. A. 2005; Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11:Suppl. 433–42 [View Article][PubMed]
    [Google Scholar]
  13. Dathe M., Schümann M., Wieprecht T., Winkler A., Beyermann M., Krause E., Matsuzaki K., Murase O., Bienert M. 1996; Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 35:12612–12622 [View Article][PubMed]
    [Google Scholar]
  14. De Kraker M. E., Wolkewitz M., Davey P. G., Koller W., Berger J., Nagler J., Icket C., Kalenic S., Horvatic J. other authors 2011; Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 55:1598–1605 [View Article][PubMed]
    [Google Scholar]
  15. Geetha K. M., Sridhar C., Murugan V. 2010a; Antioxidant and gastroprotective activities of Rhodomyrtus tomentosa (Ait.) Hassk. Int J Pharmatech Res 2:283–291
    [Google Scholar]
  16. Geetha K. M., Sridhar C., Murugan V. 2010b; Antioxidant and healing effect of aqueous alcoholic extract of Rhodomyrtus tomentosa (Ait.) Hassk on chronic gastric ulcers in rats. J Pharm Res 3:2860–2862
    [Google Scholar]
  17. Gibbons S. 2008; Phytochemicals for bacterial resistance–strengths, weaknesses and opportunities. Planta Med 74:594–602 [View Article][PubMed]
    [Google Scholar]
  18. Gould I. M. 2008; The epidemiology of antibiotic resistance. Int J Antimicrob Agents 32:Suppl. 1S2–S9 [View Article][PubMed]
    [Google Scholar]
  19. Hiranrat A., Mahabusarakam W. 2008; New acylphloroglucinols from the leaves of Rhodomyrtus tomentosa . Tetrahedron 64:11193–11197 [View Article]
    [Google Scholar]
  20. Howden B. P., Johnson P. D. R., Ward P. B., Stinear T. P., Davies J. K. 2006; Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50:3039–3047 [View Article][PubMed]
    [Google Scholar]
  21. Izzo A. A., Ernst E. 2009; Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69:1777–1798 [View Article][PubMed]
    [Google Scholar]
  22. Koehn F. E., Carter G. T. 2005; The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206–220 [View Article][PubMed]
    [Google Scholar]
  23. Kruger W. M. A., Tanuri M., De Almeida D. F. 1988; Isolation and characterization of drug-resistant mutants of Herpetomonas samuelpessoai (Kinetoplastida, Trypanosomatidae). Rev Brazil Genet 11:237–251
    [Google Scholar]
  24. Liebowitz L. D., Saunders J., Chalkley L. J., Koornhof H. J. 1988; In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide. Antimicrob Agents Chemother 32:24–26 [View Article][PubMed]
    [Google Scholar]
  25. Lim K. T., Yasin R., Yeo C. C., Puthucheary S., Thong K. L. 2009; Characterization of multidrug resistant ESBL-producing Escherichia coli isolates from hospitals in Malaysia. J Biomed Biotechnol 2009:1–10 [View Article][PubMed]
    [Google Scholar]
  26. Limsuwan S., Trip E. N., Kouwen T. R., Piersma S., Hiranrat A., Mahabusarakam W., Voravuthikunchai S. P., van Dijl J. M., Kayser O. 2009; Rhodomyrtone: a new candidate as natural antibacterial drug from Rhodomyrtus tomentosa . Phytomedicine 16:645–651 [View Article][PubMed]
    [Google Scholar]
  27. Limsuwan S., Hesseling-Meinders A., Voravuthikunchai S. P., van Dijl J. M., Kayser O. 2011; Potential antibiotic and anti-infective effects of rhodomyrtone from Rhodomyrtus tomentosa (Aiton) Hassk. on Streptococcus pyogenes as revealed by proteomics. Phytomedicine 18:934–940 [View Article][PubMed]
    [Google Scholar]
  28. Lv J., Yin L., Liu T., Wang Y. 2007; Synthesis of pseudopeptides based l-tryptophan as a potential antimicrobial agent. Bioorg Med Chem Lett 17:1601–1607 [View Article][PubMed]
    [Google Scholar]
  29. McKay G. A., Beaulieu S., Arhin F. F., Belley A., Sarmiento I., Parr T. Jr, Moeck G. 2009; Time–kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium . J Antimicrob Chemother 63:1191–1199 [View Article][PubMed]
    [Google Scholar]
  30. Menichetti F. 2005; Current and emerging serious Gram-positive infections. Clin Microbiol Infect 11:Suppl. 322–28 [View Article][PubMed]
    [Google Scholar]
  31. Mohamed G. A., Ibrahim S. R. M. 2007; Eucalyptone G, a new phloroglucinol derivative and other constituents from Eucalyptus globulus Labill. ARKIVOC 15:281–291 [CrossRef]
    [Google Scholar]
  32. Moore C. L., Lu M., Cheema F., Osaki-Kiyan P., Perri M. B., Donabedian S., Haque N. Z., Zervos M. J. 2011; Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool. Antimicrob Agents Chemother 55:4581–4588 [View Article][PubMed]
    [Google Scholar]
  33. Njume C., Afolayan A. J., Samie A., Ndip R. N. 2011; Inhibitory and bactericidal potential of crude acetone extracts of Combretum molle (Combretaceae) on drug-resistant strains of Helicobacter pylori . J Health Popul Nutr 29:438–445 [View Article][PubMed]
    [Google Scholar]
  34. Ong H. C., Nordiana M. 1999; Malay ethno-medico botany in Machang, Kelantan, Malaysia. Fitoterapia 70:502–513 [View Article]
    [Google Scholar]
  35. Oonmetta-aree J., Suzuki T., Gasaluck P., Eumkeb G. 2006; Antimicrobial properties and action of galangal (Alpinia galanga Linn.) on Staphylococcus aureus . LWT 39:1214–1220 [View Article]
    [Google Scholar]
  36. Rivera A. M., Boucher H. W. 2011; Current concepts in antimicrobial therapy against select Gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc 86:1230–1243 [View Article][PubMed]
    [Google Scholar]
  37. Saising J., Ongsakul M., Voravuthikunchai S. P. 2011; Rhodomyrtus tomentosa (Aiton) Hassk. ethanol extract and rhodomyrtone: a potential strategy for the treatment of biofilm-forming staphylococci. J Med Microbiol 60:1793–1800 [View Article][PubMed]
    [Google Scholar]
  38. Salni D., Sargent M. V., Skelton B. W., Soediro I., Sutisna M., White A. H., Yulinah E. 2002; Rhodomyrtone, an antibiotic from Rhodomyrtus tomentosa . Aust J Chem 55:229–232 [View Article]
    [Google Scholar]
  39. Sianglum W., Srimanote P., Wonglumsom W., Kittiniyom K., Voravuthikunchai S. P. 2011; Proteome analyses of cellular proteins in methicillin-resistant Staphylococcus aureus treated with rhodomyrtone, a novel antibiotic candidate. PLoS ONE 6:1–10 [View Article][PubMed]
    [Google Scholar]
  40. Sievert D. M., Rudrik J. T., Patel J. B., McDonald L. C., Wilkins M. J., Hageman J. C. 2008; Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin Infect Dis 46:668–674 [View Article][PubMed]
    [Google Scholar]
  41. Smith T. L., Pearson M. L., Wilcox K. R., Cruz C., Lancaster M. V., Robinson-Dunn B., Tenover F. C., Zervos M. J., Band J. D. et al. Glycopeptide-Intermediate Staphylococcus aureus Working Group 1999; Emergence of vancomycin resistance in Staphylococcus aureus.. N Engl J Med 340:493–501 [View Article][PubMed]
    [Google Scholar]
  42. Tenney J. H., Maack R. W., Chippendale G. R. 1983; Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrob Agents Chemother 23:188–189 [View Article][PubMed]
    [Google Scholar]
  43. Visutthi M., Srimanote P., Voravuthikunchai S. P. 2011; Responses in the expression of extracellular proteins in methicillin-resistant Staphylococcus aureus treated with rhodomyrtone. J Microbiol 49:956–964 [View Article][PubMed]
    [Google Scholar]
  44. Voravuthikunchai S. P., Dolah S., Charernjiratrakul W. 2010; Control of Bacillus cereus in foods by Rhodomyrtus tomentosa (Ait.) Hassk. Leaf extract and its purified compound. J Food Prot 73:1907–1912[PubMed] [CrossRef]
    [Google Scholar]
  45. Walsh C. 2003; Where will new antibiotics come from?. Nat Rev Microbiol 1:65–70 [View Article][PubMed]
    [Google Scholar]
  46. Walsh F. M., Amyes S. G. B. 2004; Microbiology and drug resistance mechanisms of fully resistant pathogens. Curr Opin Microbiol 7:439–444 [View Article][PubMed]
    [Google Scholar]
  47. Wei F. 2006a Manufacture of oral liquid containing traditional Chinese medicine extract for treating gynecopathy [Guangxi Huahong Pharmaceutical Co., Ltd, People’s Republic of China; Shanghai Fosun Pharmaceutical (Group) Co., Ltd], Faming Zhuanli Shenqing Gongkai Shuomingshu. People’s Republic of China patent CN1846715
  48. Wei F. 2006b Manufacture of traditional Chinese medicine composition for treating urinary tract infection [Gungxi Huahong Pharmaceutical Co., Ltd, People’s Republic of China; Shanghai Fosun Pharmaceutical (Group) Co., Ltd], Faming Zhuanli Shenqing Gongkai Shuomingshu. People’s Republic of China patent CN1853687
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.049205-0
Loading
/content/journal/jmm/10.1099/jmm.0.049205-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error